Aegis initiated coverage on shares of Acasti Pharma (NASDAQ:ACST) in a report released on Tuesday, The Fly reports. The brokerage issued a buy rating on the biopharmaceutical company’s stock.

A number of other research firms have also recently weighed in on ACST. HC Wainwright reissued a buy rating on shares of ACASTI PHARM-TS in a research report on Wednesday, June 26th. ValuEngine raised shares of WPP from a sell rating to a hold rating in a research report on Wednesday, June 19th. Finally, Zacks Investment Research cut shares of Home Bancshares from a hold rating to a sell rating in a research report on Friday, June 7th.

NASDAQ:ACST opened at $1.40 on Tuesday. The firm has a 50-day moving average price of $1.04. The stock has a market cap of $109.86 million, a PE ratio of -1.97 and a beta of 1.15. Acasti Pharma has a 1-year low of $0.43 and a 1-year high of $1.80.

A number of large investors have recently bought and sold shares of the business. Geode Capital Management LLC bought a new position in shares of Acasti Pharma during the fourth quarter worth about $40,000. Pura Vida Investments LLC bought a new position in shares of Acasti Pharma during the fourth quarter worth about $157,000. Finally, Perceptive Advisors LLC bought a new position in shares of Acasti Pharma during the fourth quarter worth about $1,480,000. 3.12% of the stock is owned by institutional investors.

About Acasti Pharma

Acasti Pharma Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia.

Featured Article: Bollinger Bands

The Fly

Receive News & Ratings for Acasti Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acasti Pharma and related companies with MarketBeat.com's FREE daily email newsletter.